

References

I-34

1. Khoja, L Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. *Oncology Letters*. 2016;1581-1585.
2. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Two-year overall survival rates from a randomized phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. *Lancet Oncol*. 2016;17(11):1558-1568.
3. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;883-895.
4. National Comprehensive Cancer Network® (NCCN). 2020. Drugs and Biologics Compendium. Ipilimumab.
5. Yervoy (ipilimumab) injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 10/2020.
6. Micromedex®Solutions Compendia. 2020. Ipilimumab.
7. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Ipilimumab.
8. Grosso JF and Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. *Cancer Immunity*. 2013;13:1-14.
9. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profiles of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. *J Clin Oncol*. 2017;35(34):3815-3826.
10. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology*. 2018;36(8):773-779.
11. Ipilimumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
12. Hayes, Inc. Evidence Analysis Research Brief. Yervoy (ipilimumab) for treatment of metastatic non-small cell lung cancer. Lansdale, PA: Hayes, Inc.; April 5, 2019.
13. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the

checkmate 032 randomized cohort. *Journal of Thoracic Oncology*. 2020;15(5):426-435.

14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*. 2019;381:1535-1546.
15. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med*. 2018;378(22):2093-2104.